Angela Lamarca· @DrAngelaLamarca · X·· 2 天前评分70
正文 · 原文
iKRAS #Daraxonrasib in pretreated #PDAC at @myESMO #ESMO26
‼️Subgroup analysis (careful with statistical power)
👉PFS benefit for G12D, G12V and G12R
👉OS benefit for all but challenging due to small numbers
👉ORR varies
#ESMOAmbassadors
399 浏览 · 6 赞 · 3 转发 · 1 回复
会议摘要
LBA82按 Proffered paper 1: Gastrointestinal tumour, upper digestive 对上
Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Additional subgroup analyses from the ph3 RASolute 302 study
https://esmocongress.esmo.org帖内回复
- Angela Lamarca@DrAngelaLamarca
@myESMO PDAC #guidelines (update August 2026) state: “greatest strength of evidence (…) KRAS G12-mutated” - acknowledged discrepancies between authors https://annalsofoncology.org/action/showPdf… #ESMOAmbassadors #ESMO26
来源：Angela Lamarca · x.com